Skin Cancer Market Research Report-  Asia Pacific Forecast till 2027

Skin Cancer Market Information: By Type (Basal Cell Carcinoma, Squamous Cell Carcinoma), Treatment (Non-Invasive, Chemotherapy, Surgical), End Users (Hospital and Clinics, Diagnostic Centers, Cancer Research Institute) - Asia Pacific Forecasted till 2027

ID: MRFR/Pharma/0667-HCR | October 2022 | Region: Global | 80 Pages         

skin cancer Market Speak to Analyst Request a Free Sample

Asia Pacific Skin Cancer Market Scenario

Asia Pacific skin cancer market is expected to grow at a CAGR of 8.8% during the forecasted period. Skin cancer is the most common type of cancer, which arise due to uncontrolled growth of abnormal skin cells. It occurs when skin cells are damaged by unrepaired DNA or genetic defects that lead the uncontrolled growth of cells in the skin. Over 100 types of cancer are found across the globe, but skin cancer is the most common form of cancer, which accounts for at least 30% of total cancer cases. The prevalence of skin cancer is increasing owing to depleting ozone level and increasing solar UV radiation entering the Earth's surface. According to the WHO, it is estimated that a 10% decrease in the ozone level is likely to result in an additional 300,000 non-melanoma and 4,500 melanoma skin cancer cases.

There are three major types of cancer: basal cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. The basal cell skin cancer is the most common type of cancer. The major cause of the skin cancer is overexposure to harmful radiation and HPV infections, which increases the risk of skin cancer. The major driving factor for the growth of the Asia Pacific skin cancer market is increasing the prevalence of skin cancer. Furthermore, extensive R&D pipelines and increasing usage of combination therapies have fueled the growth of the market. On another hand, stringent regulatory guidelines, side effects associated with the treatment and long approval time for the drugs may hamper the growth of the market over the review period.

Figure: Asia Pacific skin cancer market by type, market share, 2016 (%) Asia Pacific skin cancer Market

Sources: Annual reports, Press release, White paper, Company presentation

Asia Pacific Skin Cancer Market Segmentations The Asia Pacific skin cancer market is segmented on the basis of type, treatment, and end users.

On the basis of the type, it is segmented into basal cell carcinoma, squamous-cell carcinoma, and melanoma.

On the basis of the treatment, it is segmented into non-invasive, chemotherapy, surgical, and other. Furthermore, non-invasive treatments are segmented into laser therapy, radiotherapy, photodynamic therapy, cryotherapy, and others. The chemotherapy is further segmented into systemic and targeted. The surgical treatment is segmented into photodynamic therapy, cryosurgery, Mohs micrographic surgery, and others.

On the basis of end users, the market is segmented into hospital and clinics, cancer diagnostic centers, cancer research institute, and other. 

Asia Pacific Skin Cancer Market Regional Analysis On the regional basis, Asia Pacific market is segmented into Japan, India, China, the Republic of Korea, Australia, and the Rest of Asia Pacific.

Asia Pacific is the fastest growing skin cancer market. Japan, Australia, and China are the major contributor to the market growth. The incidence of skin cancer per 100,000 population is 20-25 cases in Japan, 11-12 cases in China. About 80% of the cases are basal cell carcinoma (BCC), 16% squamous cell carcinoma, and 4% are melanoma.

Continuously increasing the prevalence of skin cancer in Japan is driving the growth of this region. Furthermore, increasing government support for research and continuous development in technology is an important driving factor for the growth of the Asia Pacific market.

Asia Pacific Skin Cancer Market Key Players Some of the key players in the market: F. Hoffmann-la Roche Ltd. (Switzerland), Novartis International AG (Switzerland), Sun Pharma Industries Ltd. (India), Elekta AB (Sweden), Varian Medical Systems Inc. (US), Cannabis Science Inc. (US), Cellceutix Corp. (US), LEO Pharma A/S (Denmark), Moberg Pharma AB (Sweden), Mylan Pharmaceutical Inc. (US), Oncothyreon Inc. (US), Eli Lilly and Co. (US), Bristol Myers Squibb Co. (US), Boehringer Ingelheim GmbH (Germany), Aqua Pharmaceuticals LLC (US), Valeant Pharmaceuticals Inc (Canada), Meda AB (US), iCAD Inc. (Sweden), and Merck & Co. Inc. (US).

Intended Audience

  • Skin cancer drug manufacturers

  • Skin cancer drug suppliers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Provider 

Speak to Analyst Ask for Customization